A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
← catalyst calendarSponsored by CRISPR Therapeutics AG (industry) · CRSP — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
19actual
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-13 | actual | When the study began enrolling |
| Primary completion | 2025-09-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-18 | actual | The whole study's end, after follow-up |
| First posted | 2023-04-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Clear Cell Renal Cell Carcinoma
- Cervical Carcinoma
- Esophageal Carcinoma
- Pancreatic Adenocarcinoma
- Malignant Pleural Mesothelioma
Intervention
- Biological: CTX131
Primary outcomes
what the primary-completion date above is the date OFPhase 1 (Dose Escalation): Incidence of adverse events
measured From CTX131 infusion up to 28 days post-infusion
Phase 2 (Cohort Expansion): Objective response rate (ORR)
measured From CTX131 infusion up to 60 months post-infusion
Permalink · CRSP's whole pipeline · Catalyst calendar · Every registered study · What changed